| Elotuzumab studied in …STUDIED_INderived63 of 63show fewer |
|---|
| → studied in | NCT06208150Phase 3 · active not recruiting A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07555938Phase 3 · recruiting Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06158841Phase 3 · active not recruiting Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06152575Phase 3 · recruiting MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02343042Phase 1/Phase 2 · recruiting Selinexor and Backbone Treatments of Multiple Myeloma Patients · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06785415Phase 1/Phase 2 · recruiting Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03651128Phase 3 · completed Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04517851Phase 2 · active not recruiting Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis · 63 trials list this drug (19 active) | — | — | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase,Primary Myelofibrosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05002816Phase 1/Phase 2 · active not recruiting Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05981209Phase 1 · active not recruiting Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01668719Phase 1/Phase 2 · completed S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma · 63 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02420860Phase 2 · active not recruiting Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02719613Phase 2 · completed Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04835129Phase 2 · active not recruiting Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03361306Phase 2 · completed LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05730036Phase 3 · recruiting A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02718833Phase 2 · active not recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02969837Phase 2 · completed Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03030261Phase 2 · active not recruiting Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05560399early Phase 1 · active not recruiting A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06518551Phase 1/Phase 2 · recruiting Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05028348Phase 3 · active not recruiting A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03713294Phase 2 · completed Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01729091Phase 2 · completed Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma,Plasma Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03989414Phase 1/Phase 2 · active not recruiting A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02375555Phase 2 · completed Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03000634Phase 2 · withdrawn 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06232707Phase 3 · withdrawn A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02856438no longer available Early Patient Access Treatment Use Protocol CA204-220 · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02843074Phase 2 · completed Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03155100Phase 2 · completed Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04614636Phase 1 · terminated FT538 in Subjects With Advanced Hematologic Malignancies · 63 trials list this drug (19 active) | — | — | Multiple Myeloma,Acute Myeloid Leukemia,Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02279394Phase 2 · completed E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03948035Phase 3 · active not recruiting Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03411031Phase 2 · terminated Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02726581Phase 3 · completed An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03252600Phase 2 · unknown Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis · 63 trials list this drug (19 active) | — | — | Primary Amyloidosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02654132Phase 2 · completed An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3) · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01335399Phase 3 · completed Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02272803Phase 2 · completed Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01239797Phase 3 · completed Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Lymphoma,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03104270Phase 2 · terminated Combination Study for High Risk Multiple Myeloma Patients · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03126617no longer available Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02495922Phase 3 · completed A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04584307Phase 2 · withdrawn Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02612779Phase 2 · completed A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01891643Phase 3 · terminated PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) · 63 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03003728Phase 2 · withdrawn 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT) · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03393273Phase 2 · withdrawn Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159365Phase 2 · completed Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03168100Phase 2 · withdrawn 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03227432Phase 2 · withdrawn An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03023527Phase 1 · terminated Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01478048Phase 2 · completed Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01441973Phase 2 · completed Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma · 63 trials list this drug (19 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00742560Phase 2 · completed A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02252263Phase 1 · completed A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02655458Phase 1 · completed Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01393964Phase 1 · completed Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01632150Phase 2 · completed Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02541643no longer available Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00726869Phase 1 · terminated A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies. · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00425347Phase 1 · completed Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma · 63 trials list this drug (19 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |